Progression and clinical outcome of infection due to human immunodeficiency virus

Alan R. Lifson, Nancy A. Hessol, George W. Rutherford

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Ten years into the AIDS epidemic, how are we doing? Have we managed to significantly alter the course of infection with human immunodeficiency virus (HIV)? Have we defined factors that accelerate or decelerate the rate of progression of infection to clinical disease? Are we better able to predict who is most likely to develop AIDS, to substantially alter the course of infection, and to prevent or delay HIV-related morbidity and mortality? Advances made during the past decade that have furthered our understanding of the virus itself have been remarkable. We now understand a great deal about how the virus attaches to the CD4 cell receptor; how it is internalized, transcribed onto DNA of the host, and incorporated into the host’s genome; and how its expression is latently controlled by a series of regulatory genes. However, translating this basic understanding of the virus into significant clinical advances still seems tediously slow for clinicians caring for HIV-infected individuals. I asked Dr. Alan R. Lifson of the University of California San Francisco School of Medicine and his colleagues from the San Francisco Department of Public Health and the California Department of Health Services to summarize the current status of our attempts to alter the course of HIV infection.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Volume14
Issue number4
DOIs
StatePublished - Apr 1 1992

Fingerprint

HIV
San Francisco
Viruses
Infection
Acquired Immunodeficiency Syndrome
CD4 Antigens
Virus Diseases
Regulator Genes
Health Services
Public Health
Medicine
Genome
Morbidity
Mortality
DNA

Cite this

Progression and clinical outcome of infection due to human immunodeficiency virus. / Lifson, Alan R.; Hessol, Nancy A.; Rutherford, George W.

In: Clinical Infectious Diseases, Vol. 14, No. 4, 01.04.1992.

Research output: Contribution to journalArticle

@article{f73d4e992ef545f185fa5443bf37bf8f,
title = "Progression and clinical outcome of infection due to human immunodeficiency virus",
abstract = "Ten years into the AIDS epidemic, how are we doing? Have we managed to significantly alter the course of infection with human immunodeficiency virus (HIV)? Have we defined factors that accelerate or decelerate the rate of progression of infection to clinical disease? Are we better able to predict who is most likely to develop AIDS, to substantially alter the course of infection, and to prevent or delay HIV-related morbidity and mortality? Advances made during the past decade that have furthered our understanding of the virus itself have been remarkable. We now understand a great deal about how the virus attaches to the CD4 cell receptor; how it is internalized, transcribed onto DNA of the host, and incorporated into the host’s genome; and how its expression is latently controlled by a series of regulatory genes. However, translating this basic understanding of the virus into significant clinical advances still seems tediously slow for clinicians caring for HIV-infected individuals. I asked Dr. Alan R. Lifson of the University of California San Francisco School of Medicine and his colleagues from the San Francisco Department of Public Health and the California Department of Health Services to summarize the current status of our attempts to alter the course of HIV infection.",
author = "Lifson, {Alan R.} and Hessol, {Nancy A.} and Rutherford, {George W.}",
year = "1992",
month = "4",
day = "1",
doi = "10.1093/clinids/14.4.966-a",
language = "English (US)",
volume = "14",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Progression and clinical outcome of infection due to human immunodeficiency virus

AU - Lifson, Alan R.

AU - Hessol, Nancy A.

AU - Rutherford, George W.

PY - 1992/4/1

Y1 - 1992/4/1

N2 - Ten years into the AIDS epidemic, how are we doing? Have we managed to significantly alter the course of infection with human immunodeficiency virus (HIV)? Have we defined factors that accelerate or decelerate the rate of progression of infection to clinical disease? Are we better able to predict who is most likely to develop AIDS, to substantially alter the course of infection, and to prevent or delay HIV-related morbidity and mortality? Advances made during the past decade that have furthered our understanding of the virus itself have been remarkable. We now understand a great deal about how the virus attaches to the CD4 cell receptor; how it is internalized, transcribed onto DNA of the host, and incorporated into the host’s genome; and how its expression is latently controlled by a series of regulatory genes. However, translating this basic understanding of the virus into significant clinical advances still seems tediously slow for clinicians caring for HIV-infected individuals. I asked Dr. Alan R. Lifson of the University of California San Francisco School of Medicine and his colleagues from the San Francisco Department of Public Health and the California Department of Health Services to summarize the current status of our attempts to alter the course of HIV infection.

AB - Ten years into the AIDS epidemic, how are we doing? Have we managed to significantly alter the course of infection with human immunodeficiency virus (HIV)? Have we defined factors that accelerate or decelerate the rate of progression of infection to clinical disease? Are we better able to predict who is most likely to develop AIDS, to substantially alter the course of infection, and to prevent or delay HIV-related morbidity and mortality? Advances made during the past decade that have furthered our understanding of the virus itself have been remarkable. We now understand a great deal about how the virus attaches to the CD4 cell receptor; how it is internalized, transcribed onto DNA of the host, and incorporated into the host’s genome; and how its expression is latently controlled by a series of regulatory genes. However, translating this basic understanding of the virus into significant clinical advances still seems tediously slow for clinicians caring for HIV-infected individuals. I asked Dr. Alan R. Lifson of the University of California San Francisco School of Medicine and his colleagues from the San Francisco Department of Public Health and the California Department of Health Services to summarize the current status of our attempts to alter the course of HIV infection.

UR - http://www.scopus.com/inward/record.url?scp=0026520869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026520869&partnerID=8YFLogxK

U2 - 10.1093/clinids/14.4.966-a

DO - 10.1093/clinids/14.4.966-a

M3 - Article

VL - 14

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -